Phase II Study of 5-Fluorouracil, Pirarubicin and Low-dose Consecutive Administration of Cisplatin for Advanced and Recurrent Gastric Cancer

Japanese Journal of Clinical Oncology

Volumn 28, Issue 5, 1998, Pages 314-317

  Kikuyama, Shigehiro ^a,c   Inada, Takao ^b   Miyakita, Makoto ^a   Ogata, Yoshiro ^b  

^a National Hospital Organization   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Cisplatin; Combination chemotherapy; Pirarubicin gastric cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; DRUG DERIVATIVE; FLUOROURACIL; FTP PROTOCOL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; LEUKOPENIA; MALE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; STOMACH TUMOR; SURVIVAL; THROMBOCYTOPENIA; TUMOR RECURRENCE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 0032061507     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.5.314     Document Type: Article

References (14)

1. Macdonald JS, Cohn I, Gunderson LL. Cancer of the stomach. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, 1985:659-90.
2. Wils J. Bleiberg H Current status of chemotherapy for gastric cancer. Eur J Cancer Clin Oncol 1989;25:3-8.
3. Scanlon KJ, Newmen EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83:8923-5.
4. Kurihara M, Kubota T, Hoshiya Y, Otani Y, Watanabe M, Kumai K, et al. Anti-tumor activity of cis-diamminedichloroplatinum(II) against human tumor xenografts depends on its area under the curve in nude mice. J Surg Oncol 1996;61:138-42.
5. Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K, et al. Pharmacokinetics of cis-diamminedichloroplatinum(II) given as low-dose and high-dose infusions. J Surg Oncol 1996;62:135-8.
6. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994;30A:2091-3.
7. Skipper HE Cancer Chemotherapy, vol 4. Ann Abor, MI: University Microfilms International, 1979;135-49.
8. Saikawa Y, Kubota T, Kuo T, Furukawa T, Kase S, Tanino H, et al. Anti-tumor activity of (2R)-4-O-tetrahydropyranyladriamycin on human gastric cancer cell lines in vitro and in vivo. Anticancer Res 1994;14:469-73.
9. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: World Health Organization, 1979.
10. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Cancer. Tokyo: Kanehara, 1995.
11. Woolley P, Smith F, Estevez R, Gisselbrecht C, Alvarez C, Boiron M, et al. A phase II trial of 5-FU, adriarnycin and cisplatin (FAP) in advanced gastric cancer. Proc Am Soc Clin Oncol 1981;22:455.
12. Rougier P, Droz JP, Theodore C, Piot G, Herait P, Ruffle P, et al. Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma. Cancer Treat Rep 1987;71:1301-2.
13. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HS. A phase II study of combined 5-fluorouracil, doxombicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986;4:1053-7.
14. Epelbaum R, Haim N, Stein M, Choen Y, Robinson E. Treatment of advanced gastric cancer with DDP (cisplatin), adriarnycin and 5-fluorouracil (DAF). Oncology 1987;44:201-6